Ascelia Pharma - Orviglance commercial opportunity and progress towards launch

Meet and ask questions to deputy CEO and CCO Julie Waras Brogren from Ascelia Pharma – Thursday the 30th of March from 9:30 to 10 AM.

Julie Waras Brogren will dive into the market size and potential of Orviglance and go-to-market strategy.

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 12:51 PM – 03/22/2023.